Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Indirect comparisons of screening strategies and generalizing effects to a nationally representative population by combining trial data

Principal Investigator
Name
Issa Dahabreh
Degrees
MD, ScD
Institution
President and Fellows of Harvard College on behalf of Harvard T.H. Chan School of Public Health
Position Title
Associate Professor
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-1130
Initial CDAS Request Approval
Dec 19, 2022
Title
Indirect comparisons of screening strategies and generalizing effects to a nationally representative population by combining trial data
Summary
The NLST compared low dose computed tomography (CT) screening versus chest radiography, while the PLCO compared chest radiography screening versus no screening, in different populations. Thus, the trial results are not directly comparable. However, it is of interest to know the effect of CT screening vs no screening, which was not evaluated in the NLST. We can indirectly compare the effect of CT screening vs no screening in the PLCO-trial eligible population.

We will also evaluate the feasibility of combining chest radiography data from the NLST and PLCO, to improve efficiency when generalizing from the trials to a nationally representative population, using other data sources, such as survey data (e.g., NHIS).
Aims

-Make indirect comparisons of the effect of CT screening vs no screening in the PLCO-trial eligible population.

-Estimate the effect of lung cancer screening in representative US target populations, using methods we have developing for transporting effects from a trial to a target population, by combining trial data or transporting the PLCO to a representative target population. We will estimate the absolute and relative rates, rate differences, and ratios for lung-cancer and all-cause mortality at a median follow-up of 6.5 years.

Collaborators

Sarah Robertson